HERAMED Limited (HMD), an ASX-listed company, is focused on the commercialization and deployment of HeraCARE pregnancy monitoring solution. The company has generated revenue related to the provision of pregnancy monitoring services under key contracts with customers through the delivery of their HeraCARE software platform and HeraBEAT monitoring devices.
ASX Code | HMD |
Website | http://www.hera-med.com |
Industry/Sector | Health Care Equipment |
Market Cap ($M) | 6 |
HMD Share Price | $0.018 |
Day High | $0.000 |
Day Low | $0.000 |
Last Close | $0.018 |
HMD Share Price Movement | - ( No change ) |
There are no dividends for HeraMED Limited (HMD). Please use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.
Headline | Annoucement date/time+ | Price at announcement+ | Current price+ | Price 7D Avg | Gain/Loss |
---|---|---|---|---|---|
Final Director's Interest Notice - RW | 3 May 2024 4:29PM | $0.018 | $0.018 | $0.018 | fallen by 0% |
Non-Executive Director resignation | 1 May 2024 10:07AM | $0.018 | $0.018 | $0.018 | fallen by 0% |
Notice of Annual General Meeting/Proxy Form | 30 Apr 2024 11:25AM | $0.018 | $0.018 | $0.018 | fallen by 0% |
See all ASX announcements from HeraMED Limited (HMD) or use our ASX Announcements tool to search for announcements across all ASX-listed securities.
Year to Dec | NPAT | EPS | EPS chg (%) | PER | DPS | Yield (%) | Franking (%) |
---|---|---|---|---|---|---|---|
2023A | -$6.58 | -$2.40 | -24.90% | 0.00 | 0.00 | 0.00% | 0.0% |
2022A | -$7.20 | -$3.30 | -24.10% | 0.00 | 0.00 | 0.00% | 0.0% |
2021A | -$7.74 | -$4.30 | 27.80% | 0.00 | 0.00 | 0.00% | 0.0% |
Company | Mkt Cap | EPS Growth (%) | P/E (%) | Dividend Yield (%) | ||||||
---|---|---|---|---|---|---|---|---|---|---|
2021 A | 2022 A | 2023 A | 2021 A | 2022 A | 2023 A | 2021 A | 2022 A | 2023 A | ||
Cochlear (COH) | $20,715M | 0.1063 | 0.3407 | 0.1157 | 68.3014 | 50.9455 | 45.6611 | 1.04% | 1.33% | 1.53% |
Fisher & Paykel Hlth (FPH) | $14,862M | -0.3337 | 0.0099 | 0.3119 | 63.2298 | 62.6076 | 47.7217 | 1.60% | 1.28% | 1.42% |
HeraMED (HMD) | $6M | -0.2492 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
ResMed (RMD) | $20,462M | 0.1879 | 0.1431 | 0.1240 | 35.7367 | 31.2624 | 27.8143 | 0.62% | 0.84% | 0.95% |
Earnings | P/E Ratio | P/B Ratio | P/E Growth | |
---|---|---|---|---|
Company | 0.00 | 0.00 | 8.33 | 0.00 |
Market | 0.46 | 15.00 | 1.10 | 1.06 |
Sector | 0.90 | 31.40 | 2.37 | 2.38 |
Name | Position | Start Date |
---|---|---|
Mr David Hinton | Non-Executive Director | 21 Aug 2018 |
Mr Timothy (Tim) Chapman | Non-Executive Director | 11 Mar 2024 |
Date of change | Director | Buy/Sell | Security Type | Qty | Trade Price | Value |
---|---|---|---|---|---|---|
28 Mar 2024 | HINTON, David | Buy | Indirect Shares | 71,667 | $0.020 | $1,433.340 |
28 Mar 2024 | HINTON, David | Issued | Indirect Shares | 71,667 | $0.020 | $1,433.340 |
23 Mar 2023 | WEINBERGER, Ronald (Ron) | Buy | Direct Shares | 215,000 | $0.114 | $24,553.000 |
See all changes in directors' interest & trades for HeraMED Limited (HMD) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.
Name | Position |
---|---|
Sivan Sadan | Chief Financial Officer |
Cameron Jones | Chief Financial Officer,Company Secretary |
Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in HeraMED Limited (HMD). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.
Holding | Name |
---|---|
12,187,408 (5.02%) | Citicorp Nominees Pty Ltd |
Date | Event |
---|---|
27 March 2025 | Report (Annual) |
27 February 2025 | Report (Prelim) |
16 August 2024 | Report (Interim) |
HeraMED Limited's (HMD) current share price is $0.02. This constitutes a price movement of 0% when compared to the share price 7 days ago and is -80.34% below HMD's 12-month high of $0.09 per share. Prices are delayed by at least 20 minutes.
Relative to the previous close share price of $0.02, HeraMED Limited's (HMD) current share price of $0.02 constitutes a movement of or 0%. HeraMED Limited's (HMD) share price movement is 0% when compared to 7 days ago and is -80.34% below HMD's 52-week high of $0.09.
HeraMED Limited's (HMD) 52-week high is $0.09 which was reached on 18 May 2023. Relative to this, HMD's current share price of $0.02 constitutes a -$0.07 or -80.34% drop since that high of $0.09 per HMD share.
HeraMED Limited's (HMD) 52-week low is $0.02 which was reached on 30 Jan 2024. Relative to this, HMD's current share price of $0.02 constitutes a $0.00 or 2.94% gain since that low of $0.02 per HMD share.
Over the last 12 months, HeraMED Limited (HMD) has a daily average trading volume of 174,269 HMD shares per day.
HeraMED Limited (HMD) has a current dividend yield of n/a this year. Last year's dividend yield was 0%. The dividend yield for HMD is a ratio that tells you the percentage of HeraMED Limited's (HMD) share price that it pays out in dividends each year.
HeraMED Limited (HMD) will release its next Annual Report on 27 March 2025. HeraMED Limited's (HMD) last annual report was released on 28 Mar 2024. Click here to view HeraMED Limited's (HMD) last annual report.
HeraMED Limited (HMD) is classified as Health Care. Other companies in this sector include CSL Limited (CSL), Cochlear Limited (COH), ResMed Inc. (RMD), and Fisher & Paykel Healthcare Corporation Limited (FPH).
The price-to-earnings (P/E) ratio for HeraMED Limited (HMD) is 0. The price-to-earnings ratio, also known as P/E ratio, P/E, or PER, is the ratio of HeraMED Limited's (HMD) share price to its earnings per HMD share.
DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.
Data shown on this website is sourced by Morningstar
© 2017 Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate,
complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892)
and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and,
if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest.
No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser.
Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.